Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarin Co. plc stock logo
AMRN
Amarin
$0.88
$0.99
$0.65
$1.49
$360.82M1.981.99 million shs657,243 shs
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
$5.03
-1.2%
$5.31
$4.71
$12.43
$727.43M1.362.16 million shs785,988 shs
Cryoport, Inc. stock logo
CYRX
Cryoport
$16.23
+0.7%
$16.86
$9.00
$24.17
$797.93M1.6447,868 shs357,662 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$204.65
-6.3%
$244.64
$119.76
$322.67
$4.35B-0.47528,232 shs575,483 shs
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$70.13
-1.5%
$70.88
$55.96
$75.31
$3.48B0.52239,376 shs170,775 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarin Co. plc stock logo
AMRN
Amarin
+2.03%-1.41%+2.75%-23.19%-33.08%
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
+0.79%+1.80%+2.41%-35.41%-52.65%
Cryoport, Inc. stock logo
CYRX
Cryoport
+0.31%-5.29%-8.47%+8.41%-27.24%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
+2.29%-6.27%-12.01%-2.03%-28.61%
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
+2.04%+4.65%-2.76%+15.85%+14.14%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amarin Co. plc stock logo
AMRN
Amarin
0.2044 of 5 stars
1.93.00.00.00.00.00.6
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
0.6594 of 5 stars
3.41.00.00.00.90.00.6
Cryoport, Inc. stock logo
CYRX
Cryoport
1.2949 of 5 stars
2.12.00.00.02.83.30.6
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
4.6928 of 5 stars
4.41.00.04.63.24.20.6
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
4.3505 of 5 stars
3.34.00.83.52.82.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amarin Co. plc stock logo
AMRN
Amarin
1.75
Reduce$1.0823.30% Upside
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
2.75
Moderate Buy$10.0098.81% Upside
Cryoport, Inc. stock logo
CYRX
Cryoport
2.29
Hold$18.6314.76% Upside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.73
Moderate Buy$356.7374.31% Upside
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
2.50
Moderate Buy$110.0056.85% Upside

Current Analyst Ratings

Latest PBH, AUPH, CYRX, MDGL, and AMRN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2024
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageUnderperform$150.00
4/4/2024
Cryoport, Inc. stock logo
CYRX
Cryoport
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$17.00 ➝ $21.00
3/20/2024
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$325.00 ➝ $405.00
3/15/2024
Cryoport, Inc. stock logo
CYRX
Cryoport
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$14.50 ➝ $17.00
3/15/2024
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$405.00 ➝ $425.00
3/15/2024
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$338.00 ➝ $377.00
3/15/2024
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$320.00 ➝ $375.00
3/15/2024
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$351.00 ➝ $397.00
3/15/2024
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$382.00 ➝ $389.00
3/15/2024
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$349.00 ➝ $390.00
3/15/2024
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$337.00 ➝ $410.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amarin Co. plc stock logo
AMRN
Amarin
$306.91M1.18N/AN/A$1.35 per share0.65
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
$175.51M4.14N/AN/A$2.63 per share1.91
Cryoport, Inc. stock logo
CYRX
Cryoport
$233.26M3.42$0.40 per share41.05$9.45 per share1.72
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/A$20.53 per shareN/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$1.13B3.07$5.03 per share13.93$29.12 per share2.41

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amarin Co. plc stock logo
AMRN
Amarin
-$59.11M-$0.14N/AN/AN/A-19.26%-10.47%-6.97%5/1/2024 (Confirmed)
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
-$78.02M-$0.54N/A9.15N/A-44.45%-20.10%-14.84%5/2/2024 (Confirmed)
Cryoport, Inc. stock logo
CYRX
Cryoport
-$99.59M-$2.20N/AN/AN/A-42.69%-11.86%-5.99%5/2/2024 (Estimated)
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$373.63M-$19.94N/AN/AN/AN/A-219.39%-98.75%5/7/2024 (Confirmed)
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
-$82.31M-$1.64N/A15.211.89-7.11%14.09%6.39%5/2/2024 (Estimated)

Latest PBH, AUPH, CYRX, MDGL, and AMRN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$6.06N/A+$6.06N/AN/AN/A  
5/2/2024N/A
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
-$0.17N/A+$0.17N/AN/AN/A  
5/1/2024N/A
Amarin Co. plc stock logo
AMRN
Amarin
-$0.0350N/A+$0.0350N/AN/AN/A  
3/12/2024Q4 2023
Cryoport, Inc. stock logo
CYRX
Cryoport
-$0.32-$0.51-$0.19$0.29$58.27 million$57.26 million
2/29/2024Q4 2023
Amarin Co. plc stock logo
AMRN
Amarin
-$0.05-$0.01+$0.04-$0.01$72.46 million$74.71 million
2/28/2024Q4 2023
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$5.26-$5.68-$0.42-$5.68N/AN/A
2/15/202412/31/2023
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
-$0.16-$0.19-$0.03-$0.19$45.00 million$45.10 million      
2/8/202412/31/2023
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$1.04$1.06+$0.02$1.06$280.25 million$282.74 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amarin Co. plc stock logo
AMRN
Amarin
N/AN/AN/AN/AN/A
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
Cryoport, Inc. stock logo
CYRX
Cryoport
N/AN/AN/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$1.902.71%N/AN/A N/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amarin Co. plc stock logo
AMRN
Amarin
N/A
2.80
1.80
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
0.20
5.50
4.99
Cryoport, Inc. stock logo
CYRX
Cryoport
0.82
11.73
11.16
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.28
5.38
5.38
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
0.75
3.09
1.92

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Amarin Co. plc stock logo
AMRN
Amarin
22.25%
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
36.83%
Cryoport, Inc. stock logo
CYRX
Cryoport
92.90%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
99.95%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Amarin Co. plc stock logo
AMRN
Amarin
275410.67 million402.62 millionOptionable
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
300144.62 million138.40 millionOptionable
Cryoport, Inc. stock logo
CYRX
Cryoport
1,17049.16 million44.20 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
37619.90 million15.14 millionOptionable
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
56049.65 million48.86 millionOptionable

PBH, AUPH, CYRX, MDGL, and AMRN Headlines

SourceHeadline
Zacks Research Research Analysts Lift Earnings Estimates for Prestige Consumer Healthcare Inc. (NYSE:PBH)Zacks Research Research Analysts Lift Earnings Estimates for Prestige Consumer Healthcare Inc. (NYSE:PBH)
americanbankingnews.com - April 24 at 2:24 AM
Zacks Research Brokers Increase Earnings Estimates for Prestige Consumer Healthcare Inc. (NYSE:PBH)Zacks Research Brokers Increase Earnings Estimates for Prestige Consumer Healthcare Inc. (NYSE:PBH)
marketbeat.com - April 23 at 6:14 AM
Louisiana State Employees Retirement System Invests $1.52 Million in Prestige Consumer Healthcare Inc. (NYSE:PBH)Louisiana State Employees Retirement System Invests $1.52 Million in Prestige Consumer Healthcare Inc. (NYSE:PBH)
marketbeat.com - April 21 at 5:08 AM
Heres Why You Should Retain Prestige Consumer (PBH) Stock NowHere's Why You Should Retain Prestige Consumer (PBH) Stock Now
zacks.com - April 19 at 8:45 AM
Allspring Global Investments Holdings LLC Sells 44,747 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)Allspring Global Investments Holdings LLC Sells 44,747 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)
marketbeat.com - April 11 at 6:50 AM
Heres Why Prestige Consumer Healthcare (PBH) is a Strong Value StockHere's Why Prestige Consumer Healthcare (PBH) is a Strong Value Stock
zacks.com - April 8 at 10:41 AM
Advisors Preferred LLC Takes Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)Advisors Preferred LLC Takes Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)
marketbeat.com - April 5 at 5:44 PM
Dramamine® Celebrates its 75th Anniversary by Reviving an Unexpected Partner: The Barf BagDramamine® Celebrates its 75th Anniversary by Reviving an Unexpected Partner: The Barf Bag
globenewswire.com - April 3 at 11:57 AM
Prestige Consumer (PBH) Banks on its Portfolio Amid Cost WoesPrestige Consumer (PBH) Banks on its Portfolio Amid Cost Woes
zacks.com - April 2 at 10:11 AM
Vanguard Group Inc. Sells 37,508 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)Vanguard Group Inc. Sells 37,508 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)
marketbeat.com - March 28 at 4:15 AM
Heres Why Prestige Consumer Healthcare (PBH) is a Strong Momentum StockHere's Why Prestige Consumer Healthcare (PBH) is a Strong Momentum Stock
zacks.com - March 25 at 10:56 AM
Prestige Consumer Healthcare Inc.Prestige Consumer Healthcare Inc.
wsj.com - March 23 at 6:10 PM
Is Prestige Consumer Healthcare Inc. (NYSE:PBH) Trading At A 49% Discount?Is Prestige Consumer Healthcare Inc. (NYSE:PBH) Trading At A 49% Discount?
finance.yahoo.com - March 23 at 10:07 AM
Why Prestige Consumer Healthcare (PBH) is a Top Value Stock for the Long-TermWhy Prestige Consumer Healthcare (PBH) is a Top Value Stock for the Long-Term
zacks.com - March 21 at 11:46 AM
Perrigo has no exposure to infant formula litigation, CG saysPerrigo has no exposure to infant formula litigation, CG says
msn.com - March 15 at 6:48 PM
Analysts Are Bullish on These Healthcare Stocks: Prestige Consumer Healthcare (PBH), Madrigal Pharmaceuticals (MDGL)Analysts Are Bullish on These Healthcare Stocks: Prestige Consumer Healthcare (PBH), Madrigal Pharmaceuticals (MDGL)
markets.businessinsider.com - March 8 at 12:58 PM
Reasons to Retain Prestige Consumer (PBH) Stock for NowReasons to Retain Prestige Consumer (PBH) Stock for Now
zacks.com - March 5 at 1:56 PM
Why Prestige Consumer Healthcare (PBH) is a Top Momentum Stock for the Long-TermWhy Prestige Consumer Healthcare (PBH) is a Top Momentum Stock for the Long-Term
zacks.com - February 29 at 10:56 AM
PBH Mar 2024 55.000 putPBH Mar 2024 55.000 put
finance.yahoo.com - February 18 at 3:14 PM
PBH Jul 2024 70.000 callPBH Jul 2024 70.000 call
finance.yahoo.com - February 18 at 10:14 AM
Insider Sell: CFO Christine Sacco Sells 30,019 Shares of Prestige Consumer Healthcare Inc (PBH)Insider Sell: CFO Christine Sacco Sells 30,019 Shares of Prestige Consumer Healthcare Inc (PBH)
finance.yahoo.com - February 16 at 9:15 PM
Prestige Consumer Healthcare Inc. (NYSE:PBH) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?Prestige Consumer Healthcare Inc. (NYSE:PBH) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
finance.yahoo.com - February 11 at 8:39 AM
Prestige Consumer Healthcare Begins Sharing Financial ResultsPrestige Consumer Healthcare Begins Sharing Financial Results
msn.com - February 9 at 2:53 PM
Prestige Consumer Healthcare Third Quarter 2024 Earnings: EPS Beats ExpectationsPrestige Consumer Healthcare Third Quarter 2024 Earnings: EPS Beats Expectations
finance.yahoo.com - February 9 at 9:52 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Amarin logo

Amarin

NASDAQ:AMRN
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Aurinia Pharmaceuticals logo

Aurinia Pharmaceuticals

NASDAQ:AUPH
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Cryoport logo

Cryoport

NASDAQ:CYRX
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.
Madrigal Pharmaceuticals logo

Madrigal Pharmaceuticals

NASDAQ:MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Prestige Consumer Healthcare logo

Prestige Consumer Healthcare

NYSE:PBH
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.